Arrayjet’s ArrayPlex platform selected by Immunome for use in its discovery of targeted cancer therapies Post author: Post published:March 18, 2024 Post category:uncategorized Immunome signs deal to use Arrayjet platform in its in-house screening operations. You Might Also Like Researchers uncover why the TP53 gene is especially prone to mutations in cancer October 24, 2024 Targeted therapy and immunotherapy improve outcomes in rare thyroid cancer October 24, 2024 Knowledge gaps in identifying subtle breast cancer symptoms exposed by survey October 17, 2023